DAVID POPLACK to Infusions, Intravenous
This is a "connection" page, showing publications DAVID POPLACK has written about Infusions, Intravenous.
Connection Strength
0.276
-
Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000; 45(3):259-64.
Score: 0.038
-
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
Score: 0.024
-
A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia. Cancer Chemother Pharmacol. 1992; 30(2):155-7.
Score: 0.022
-
Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. Cancer Res. 1990 Dec 15; 50(24):7915-9.
Score: 0.020
-
Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. Invest New Drugs. 1990 May; 8(2):181-2.
Score: 0.020
-
A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol. 1990; 26(5):343-4.
Score: 0.019
-
Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res. 1989 Sep 15; 49(18):5213-6.
Score: 0.019
-
Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr. 1989 May; 114(5):880-4.
Score: 0.018
-
The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med. 1989 Feb 15; 110(4):279-85.
Score: 0.018
-
Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. Pain. 1987 Sep; 30(3):339-348.
Score: 0.016
-
Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):26-30.
Score: 0.009
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
Score: 0.008
-
Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6.
Score: 0.008
-
A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clin Cancer Res. 1997 May; 3(5):713-7.
Score: 0.008
-
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr; 15(4):1538-43.
Score: 0.008
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.008
-
Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst. 1994 Jan 19; 86(2):143-5.
Score: 0.006
-
Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr. 1990 Dec; 117(6):980-5.
Score: 0.005